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A 52-year-old male, diagnosed with paraganglioma of the urinary bladder, underwent transurethral
resection of the bladder tumor 10 years ago. He was lost to follow-up after the operation but was recently
admitted toourhospital for the treatmentof nasopharyngeal cancer. However, refractory hypertensionwith
palpitation was noted and a computed tomography scan revealed a round, well-deﬁned mass at the right
pelvic region. Retroperitoneal tumor excision surgery was performed and a subsequent pathological anal-
ysis revealed paraganglioma. The diagnosis of paraganglioma of the urinary bladder with pelvic metastasis
was conﬁrmed and his blood pressure returned to normal level without medication after the operation.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
Catecholamine-secreting tumors that arise from chromafﬁn
cells of the adrenal medulla and the sympathetic ganglia are
referred to as pheochromocytomas and catecholamine-secreting
paragangliomas (extra-adrenal pheochromocytomas), respec-
tively. Approximately 10% of pheochromocytomas originate from
extra-adrenal organs, primarily from para-aortic sympathetics.
Bladder pheochromocytoma is a rare neoplasm accounting for less
than 1% of all pheochromocytomas1 and less than 0.06% of all
bladder tumors.2 The bladder pheochromocytomas usually arise
from submucosal or muscularis propria and not from perivesical
tissue and they are most common in the trigone region.3 Malignant
pheochromocytomas are histologically and biochemically the same
as benign ones. The only reliable clue to the presence of a malignant
pheochromocytoma is local invasion or distant metastases, which
may occur as long as 20 years after a resection. We herein present a
case of bladder paraganglioma with pelvic metastasis and discuss
the clinical, image, and surgical ﬁndings.
2. Case report
A 52-year-oldmale had painless gross hematuria for days and he
also mentioned urination with palpitation and headache for 2aohsiung Medical University
iwan.
ng).
ciation. Published by Elsevier Taiwyears. He denied any history of hypertension or arrhythmia. An
abdominal echo showed a bladder tumor over the right side of the
urinary bladder. Cystoscopy revealed a submucosal protruding
mass (Fig. 1A) and transurethral resection (TUR) of the bladder
tumor was done on February 7, 2002. A pathological analysis
conﬁrmed paraganglioma. 123-I-metaiodobenzylguanidine (MIBG)
scintigraphy was done and the results showed low probability of
distant metastases (Fig. 1B). He was lost to follow-up in our
outpatient department after the operation.
On February 3, 2012, he was admitted to our hospital for the
treatment of nasopharyngeal cancer. However, refractory hyper-
tension as high as 170e190 mmHg (systolic blood pressure) with
palpitation was noted. Abdominal computed tomography (CT) was
arranged and a 4.2 cm  3.9 cm  4.0 cm round, well-deﬁned mass
at the right pelvic region beside the urinary bladder (Fig. 2) was
found. The 24-hour urine vanillylmandelic acid (VMA; 15.67 mg/
day) was administered (normal range: 1e7.5 mg/day).
He was transferred to our urologic ward and an oral form of
alpha blocker, terazosin hydrochloride (Hytrin), was administrated
for 1 week prior to the operation. Then, retroperitoneal tumor
excision surgery was performed on February 13, 2012. Fluctuating
blood pressure (systolic blood pressure as high as 230 mmHg)
was noted perioperatively, and sodium nitroprusside was admin-
istrated. However, it had poor response and perdipine (nicardipine)
pump, a short-acting calcium-channel blocker, was used to control
the blood pressure. We ceased surgery several times until the
systolic blood pressure returned to normal level and the tumor wasan LLC. Open access under CC BY-NC-ND license.
Fig. 1. (A) Cystoscopy showed a hypervascular, protruding mass over the right lateral wall of the urinary bladder. (B) I131-MIBG revealed a high uptake at the urinary bladder and
low probability of distant metastases. MIBG ¼ metaiodobenzylguanidine.
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the isolated tumor conﬁrmed paraganglioma (Fig. 3C and D). After
the operation, the blood pressure became normal without medi-
cation and the patient was discharged uneventfully.
3. Discussion
Paraganglioma of the urinary bladder is a rare disease and ac-
counts for 10% of extra-adrenal pheochromocytoma. The clinical
presentation of paraganglinoma of the bladder is painless hema-
turia (50e60%), hypertension (65e80%), headache, and palpitation
during micturition.3 The average age at diagnosis is the 4the5th
decade and has an incidence of approximately 1:3 in men andFig. 2. Biphasic computed tomography revealed a 4.2 cm  3.9 cm  4.0 cm round, well-de
(A) coronal view; (B) sagittal view; (C) transverse view. There was no connection betweenwomen. Malignant pheochromocytomas are deﬁned as tumors
with local invasion or distant metastases. These tumors account for
10% of all pheochromocytomas. However, extra-adrenal pheo-
chromocytomas are malignant in 29e40% of cases.4,5 Thus, extra-
adrenal pheochromocytomas might have a higher malignant po-
tential than adrenal pheochromocytomas. For this reason, long-
term follow-up should be recommended in patients with extra-
adrenal pheochromocytoma.6,7
The diagnostic tests for paraganglioma of the urinary bladder
include 24-hour urine or plasma fractionated catecholamines and
metanephrines. Because bladder paragangliomas sometimes lack
converting enzymes called phenylethanolamine N-methyl-
transferase, elevated norepinephrine levels can be found.8 Imagingﬁned and enhanced mass at the right pelvic region beside the urinary bladder (arrow):
them.
Fig. 3. (A) Macroscopic appearance revealed an encapsulated solid tumor with gray to tan cut surface without necrosis. (B) The tumor cells are round with acidophilic granular
cytoplasm and ovoid nuclei with ﬁne granular chromatin, arranged in discrete nests (the zellballen pattern) separated by a prominent vascular network (hematoxylineeosin, 200).
(C) These tumor cells are positive for NSE, chromogranin, and synaptophysin staining (NSE, 100). (D) These cells were arranged in zellballen pattern or the nests are separated by
silver-positive ﬁbrous septum (S-100, 100). NSE ¼ neuron-speciﬁc enolase.
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and I131-MIBG can provide more detail about the tumor. On ultra-
sonography, bladder paragangliomas are seen as heterogenous,
hypoechoic, and well-deﬁned lesions, but differential diagnosis
cannot be made vis-à-vis other bladder tumors. Biphasic CT shows
homogeneous hyperenhanced soft-tissue mass. MRI is superior to
CT for the demonstration of the submucosal tumor and has a higher
sensitivity (88%).9 Bladder paragangliomas are typically hypo-
intense on T1-weighted images and exhibit hyperintensity on T2-
weighted images. Ring calciﬁcation around the circumference of
the mass is another highly suggestive characteristic.
Although MRI and CT scanning provide ﬁne anatomical details
in locating these tumors, only the use of I131-MIBG allows easy,
cost-effective, whole-body scanning to help localize this
catecholamine-producing tumor. On cystography, such tumors
appear granulated and lobulated, protruding into the bladder as
globular yellowish, submucosal tumors. Irrigating the mass during
cystoscopy can be helpful in conﬁrming the diagnosis preopera-
tively as the blood pressure ﬂuctuates. Cystoscopic biopsies are
usually not advocated because positive rate is very low, they bleed
easily, and can induce blood pressure ﬂuctuation.7
The treatments of bladder pheochromocytomas are partial
cystectomy (open or laparoscopic), total cystectomy, and TUR.
However, if distant metastases are found, complete resection of the
metastatic tumors is recommended. If complete radical resection is
not available, arterial embolization, cryoablation, chemotherapy,
and MIBG radiation therapy can be considered.10 A retrospective
report revealed that systemic chemotherapy with cyclophospha-
mide, vincristine, and dacarbazine had a tumor response rate of
55% and a biochemical response rate of 72%.11
Our patient had bladder paraganglioma status post-TUR, which
was performed 10 years ago, and refractory hypertensionwas noted
recently. A metastatic pelvic mass was noted on CT scan and norecurrent bladder tumor was found. Elevated 24-hour urine VMA
conﬁrmed the diagnosis. Complete resection of the pelvic mass was
performed and a pathological analysis conﬁrmed paraganglioma.
The patient’s blood pressure returned to normal without receiving
any antihypertensive medication after the operation and repeated
close follow-up with indeﬁnite annual biochemical/imaging
screening is recommended for such patients.
In conclusion, bladder paraganglioma with pelvic metastasis is
a rare condition, and such rarity limits proper development of
therapies. Complete resection is thought to be the best policy, but
if complete resection cannot be done, alternative treatment should
be considered. Further studies in patients receiving surgery or
other therapies are necessary to establish a standard for the
disease.
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